AmMax Bio, Inc.
6
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
33.3%
2 terminated/withdrawn out of 6 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
75%
3 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
Role: lead
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
Role: lead
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
Role: lead
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
Role: lead
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
Role: lead
A Study of AMG 820 in Subjects With Advanced Solid Tumors
Role: lead
All 6 trials loaded